Proper Clinical Endpoint Adjudication is essential in ensuring clinical trials integrity. Yet, Adjudication Committees (ACs) have their own challenges when assessing complex events, avoiding undue sponsor influence, or navigating unblinded data. How do sponsors ensure ACs are functioning effectively and in compliance with GCP? All of the critical points to be aware of are presented in the Clinical Endpoint Adjudication Audit Guide created by Ethical.
Written from the perspective of an experienced consultant, Ethical’s Endpoint Adjudication Audit Guide provides many useful instructions on how to plan, conduct, and evaluate Endpoint Adjudication processes to ensure integrity, transparency, and GCP compliance. Sponsors are encouraged to conduct internal audits in order to be inspection-ready.
Key Elements of Endpoint Adjudication Inspection Readiness
The Audit Guide emphasizes that clear governance and documentation are the foundation of trustworthy Endpoint Adjudication operations. Among the critical points auditors examine are:
- The Adjudication Charter – A living document defining roles, responsibilities, governance rules, and decision-making processes. Its adequacy and timely approval are essential.
- Independence and competency – Auditors assess Adjudication committee (AC) member qualifications, financial disclosures, and safeguards against sponsor influence.
- Data protection and confidentiality – Proper handling of patient data, images, and ECGs in line with GDPR and equivalent laws.
- Documentation and decision-making – Complete records of agendas, votes, minutes, and sponsor feedback must be maintained for inspection readiness.
- Safeguards for unblinding – Ensuring trial teams remain blinded while AC review safety data.
The guide also covers practical aspects such as how to verify computerized systems supporting Endpoint Adjudication operations (e.g., eAdjudication®), validate processes, and ensure secure long-term record retention.
Timing and Planning Audits
The recommended timing for an internal Adjudication audit is when 30–40% of patients are randomized and at least a third of the foreseen adjudication cases have been adjudicated. This ensures enough data exists to evaluate processes, while still leaving room for corrective actions. The guide also outlines how to prepare Audit Plans, coordinate with the AC chairperson, and identify “Critical to Quality Factors” to focus on during the review.
Who Should Read This Guide
Whether you’re a sponsor, auditor, AC member, or QA professional, this guide equips you with the tools to:
- Strengthen Endpoint Adjudication governance and independence
- Anticipate inspector expectations
- Ensure audits deliver actionable insights
- Protect both trial integrity and patient safety
👇FILL OUT THE FORM BELOW TO REQUEST YOUR COPY
Auditing ACs is not a box-ticking exercise — It’s a cornerstone of ethical, high-quality clinical research. This guide, authored by Dimitri Stamatiadis, PhD and CEO of MAIA Consulting, distills 25+ years of global experience in clinical research into a practical roadmap for AC oversight.
